Glaxo filling gap in HIV portfolio via licensing agreement with Hoechst/Bayer for non-nucleoside RTI.
Executive Summary
GLAXO CONTINUES HIV THERAPY IN-LICENSING STRATEGY WITH HOECHST/BAYER AGREEMENT giving Glaxo Wellcome rights to develop and market the quinoxaline class of non-nucleoside reverse transcriptase inhibitors discovered as part of a research collaboration between Hoechst Marion Roussel and Bayer. Under the Feb. 12 agreement, Glaxo will make an upfront payment to Hoechst and Bayer, make a milestone payment for the first compound to reach the market and pay royalties on any product sales. The agreement is subject to antitrust review.